Tocilizumab Suppliers & Bulk Manufacturers

Available Forms: IV injection, SQ Injection

Available Strengths: IV: 80 mg/4 mL, 200 mg/10 mL, 400 mg/20 mL; SQ: 162 mg/0.9 mL (pen or syringe)

Reference Brands: Actemra®(US); RoActemra®(EU)

Category: Anti Covid Medicines

Tocilizumab is available in IV injection, SQ Injection and strengths such as IV: 80 mg/4 mL, 200 mg/10 mL, 400 mg/20 mL; SQ: 162 mg/0.9 mL (pen or syringe). Sourced from GMP-certified and ISO-compliant manufacturers, this API meets global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical formulation and commercial manufacturing, Tocilizumab is supplied in bulk quantities with complete regulatory support including DMF, COA, and MSDS.

Tocilizumab can be exported to over 30 countries across Asia, Africa, Europe, and Latin America. Flexible packaging, competitive pricing, and a verified supplier network make Pharmatradz a trusted sourcing partner for pharmaceutical companies and contract manufacturers worldwide.

Product Description: Tocilizumab (brand name Actemra or RoActemra) is a monoclonal antibody used to treat severe COVID-19 complications and autoimmune conditions like rheumatoid arthritis. Available in intravenous (IV) and subcutaneous (SC) forms, it comes in strengths such as 80 mg, 200 mg, 400 mg IV vials, and 162 mg SC pens/syringes. Approved in the US, EU, and global markets, Tocilizumab is in high demand for hospitals and critical care. Through trusted PharmaB2B platforms, buyers can connect with certified Tocilizumab manufacturers, exporters, and distributors, ensuring regulatory-compliant sourcing, bulk availability, and fast international delivery for institutional and government tenders.